Read by QxMD icon Read

Relapsing MS

Sebastian Kroiss, Florian Rathe, Robert Sader, Paul Weigl, Markus Schlee
OBJECTIVES: The present preference clinical trial compared the long-term outcome of acellular dermal matrix allograft (ADMA) versus autogenous connective tissue graft (CTG) in the treatment of gingival recessions. METHOD AND MATERIALS: Thirty-nine consecutive patients with 233 Miller Class I and II recessions were treated by one operator (MS) with coronally advanced flaps and in addition either ADMA or CTG harvested from their palate. Clinical parameters were measured by an independent and masked assessor at baseline, 6 months, and 5 years...
2019: Quintessence International
Alessandro d'Ambrosio, Paola Valsasina, Antonio Gallo, Nicola De Stefano, Deborah Pareto, Frederik Barkhof, Olga Ciccarelli, Christian Enzinger, Gioacchino Tedeschi, M Laura Stromillo, Maria J Arévalo, Hanneke E Hulst, Nils Muhlert, Marisa Koini, Massimo Filippi, Maria A Rocca
BACKGROUND: In multiple sclerosis (MS), abnormalities of brain network dynamics and their relevance for cognitive impairment have never been investigated. OBJECTIVES: The aim of this study was to assess the dynamic resting state (RS) functional connectivity (FC) on 62 relapsing-remitting MS patients and 65 sex-matched healthy controls enrolled at 7 European sites. METHODS: MS patients underwent clinical and cognitive evaluation. Between-group network FC differences were evaluated using a dynamic approach (based on sliding-window correlation analysis) and grouping correlation matrices into recurrent FC states...
March 19, 2019: Multiple Sclerosis: Clinical and Laboratory Research
Seyed Mohammad Baghbanian, Mohammad Ali Sahraian
Interferon beta (IFN-β) and glatiramer acetate (GA) are the primary therapeutic immunomodulatory agents that interfere with relapsing-remitting multiple sclerosis (RRMS), and the most commonly-used drugs as well. Induction or aggravation of other immune-mediated diseases has been reported following INF-β administration. We have reviewed the reported cases to notify the treating physicians about these rare adverse events. Although co-morbid autoimmune disorders have been reported in patients with MS, the pro-inflammatory role of disease-modifying drugs, especially INF-β, could affect and enhance this co-occurrence...
July 6, 2018: Iranian Journal of Neurology
Amir Hashemi-Meshkini, Hedieh Sadat Zekri, Hasan Karimi-Yazdi, Pardis Zaboli, Mohammad Ali Sahraian, Shekoufeh Nikfar
Background: Pegylated (PEG) interferon beta 1a has been approved by the United States Food and Drug Administration (USFDA) as an alternative to interferon beta 1a for multiple sclerosis (MS). Due to its higher price, this study aimed to evaluate the cost-effectiveness of PEG-interferon beta 1-a compared with interferon beta 1a from an Iranian payer perspective. Methods: A Markov model was designed according to health states based on Expanded Disability Status Scale (EDSS) and one-month cycles over a 10-year time horizon...
July 6, 2018: Iranian Journal of Neurology
Giancarlo Comi, Stuart Cook, Gavin Giovannoni, Peter Rieckmann, Per Soelberg Sørensen, Patrick Vermersch, Andrew Galazka, Axel Nolting, Christine Hicking, Fernando Dangond
BACKGROUND: Immune reconstitution therapies (IRT) for patients with multiple sclerosis are used for short, intermittent treatment periods to induce immune resetting and allow subsequent treatment-free periods. Cladribine tablets are postulated to be an IRT that causes selective and transient reductions in CD19+ B cells and T cells, followed by reconstitution of adaptive immune function. OBJECTIVE: To characterize long-term lymphocyte count changes in pooled data from the 2-year CLARITY and subsequent 2-year CLARITY Extension studies, and the PREMIERE registry (Long-term CLARITY cohort)...
April 2019: Multiple Sclerosis and related Disorders
Stuart Cook, Thomas Leist, Giancarlo Comi, Xavier Montalban, Gavin Giovannoni, Axel Nolting, Christine Hicking, Andrew Galazka, Elke Sylvester
BACKGROUND: Treating patients with relapsing multiple sclerosis (MS) with cladribine tablets (two times 4 or 5 days of treatment each year for 2 years) results in long-lasting efficacy, with continued stability in many patients for 4 or more years. Safety and tolerability outcomes from individual clinical studies with cladribine tablets have been reported previously. OBJECTIVE: Report safety data from an integrated analysis of clinical trials and follow-up in patients with MS to further characterize the safety profile of cladribine tablets...
April 2019: Multiple Sclerosis and related Disorders
Pasquale Annunziata, Gianni Masi, Chiara Cioni
Circulating levels of IgM anti-CD64, an immunosuppressive antibody recently identified in long-term stable multiple sclerosis (MS) patients, were found to fluctuate over time in MS patients. Antibody-positive patients showed a significantly lower annualized relapse rate value as well as reached sustained disability worsening and had a relapse in a significantly longer median time than those without antibody. Disease-modifying therapies (DMTs) only were the covariate influencing both the relapse occurrence and the disability accrual...
March 8, 2019: Journal of Neuroimmunology
Samantha Stephens, Shahriar Shams, Joshua Lee, Stephanie A Grover, Giulia Longoni, Tara Berenbaum, Marcia Finlayson, Robert W Motl, E Ann Yeh
OBJECTIVES: To examine the longitudinal relationship between physical activity and fatigue and depression among youth with demyelinating conditions. STUDY DESIGN: From September 2013 to March 2017, we performed a longitudinal study of consecutive youth diagnosed at their first visit with pediatric onset multiple sclerosis (POMS) or monophasic acquired demyelinating syndromes (mono-ADS) at a neuroinflammatory disorders clinic in a tertiary children's hospital. Fatigue was determined at each visit by the Pediatric Quality of Life Multidimensional Fatigue Scale, depressive symptoms by the Center of Epidemiologic Studies Depression Children Rating Scale, and physical activity level by the Godin Leisure Time Exercise Questionnaire...
March 13, 2019: Journal of Pediatrics
K van der Hiele, D A M van Gorp, M A P Heerings, P J Jongen, J J L van der Klink, E A C Beenakker, J J J van Eijk, S T F M Frequin, B M van Geel, G J D Hengstman, E Hoitsma, J P Mostert, W I M Verhagen, K de Gans, D Zemel, H A M Middelkoop, L H Visser
BACKGROUND: Multiple sclerosis (MS) is a chronic disorder of the central nervous system with an unpredictable disease course. Life partners often become caregivers, which can be both rewarding and challenging, as the caregiver's physical and mental health is often negatively affected. Previous studies on caregiver strain focused on caregivers of persons with MS with relatively high disability levels, while caregiver strain may already be experienced by life partners living with mildly disabled persons with MS...
March 6, 2019: Multiple Sclerosis and related Disorders
Lambros Messinis, Dimitris Apostolopoulos, Tryfon Spiridonidis, Grigorios Nasios, Aikaterini Giazkoulidou, Magda Tsolaki, Vasilis Panagiotopoulos
OBJECTIVES: Cognitive impairment is present in up to 65% of Relapsing Remitting Multiple sclerosis (RRMS) patients and can be extremely debilitating. Although deficits in episodic memory and processing speed occur more frequently than executive deficits, executive dysfunction tends to have a significant impact on MS patients' ability to generate strategies, think divergently, solve and estimate problems, and reason in abstract terms with substantial negative impacts on activities of daily living...
January 2019: Hellenic Journal of Nuclear Medicine
Mathias Due Buron, Thor Ameri Chalmer, Finn Sellebjerg, Jette Frederiksen, Monika Katarzyna Góra, Zsolt Illes, Matthias Kant, Zsolt Mezei, Thor Petersen, Peter Vestergaard Rasmussen, Homayoun Roshanisefat, Houry Hassanpour-Kalam-Roudy, Tobias Sejbæk, Anna Tsakiri, Arkadiusz Weglewski, Per Soelberg Sorensen, Melinda Magyari
OBJECTIVE: To compare on-treatment efficacy and discontinuation outcomes in teriflunomide (TFL) and dimethyl fumarate (DMF) in the treatment of relapsing-remitting multiple sclerosis (RRMS) in a real-world setting. METHODS: We identified all patients starting TFL or DMF from the Danish Multiple Sclerosis Registry and compared on-treatment efficacy outcomes between DMF using TFL, adjusted for clinical baseline variables and propensity score-based methods. RESULTS: We included 2,236 patients in the study: 1,469 patients on TFL and 767 on DMF...
March 15, 2019: Neurology
Monika Berezowska, Shelly Coe, Helen Dawes
OBJECTIVE: to examine the extent of effect vitamin D in Multiple Sclerosis (MS) on pathology and symptoms. METHODS: A literature search was performed in November 2018 (CRD42018103615). Eligibility criteria: randomised control trials in English from 2012 to 2018; a clinical diagnosis of MS; interventions containing vitamin D supplementation (vitamin D3 or calcitriol) in disease activity compared to a control/placebo; improvement in: serum 25(OH)D, relapse rates, disability status by Expanded Disability Status Scale (EDSS) scores, cytokine profile, quality of life, mobility, T2 lesion load and new T2 or T1 Gd enhancing lesions, safety and adverse effects...
March 14, 2019: International Journal of Molecular Sciences
Natalia V Voge, Enrique Alvarez
The global incidence of multiple sclerosis (MS) appears to be increasing. Although it may not be associated with a high mortality rate, this disease has a high morbidity rate which affects the quality of life of patients and reduces their ability to do their activities of daily living. Thankfully, the development of novel disease modifying therapies continues to increase. Monoclonal antibodies (MABs) have become a mainstay of MS treatment and they are likely to continue to be developed for the treatment of this disease...
March 14, 2019: Biomedicines
Valerie J Block, Riley Bove, Chao Zhao, Priya Garcha, Jennifer Graves, Andrew R Romeo, Ari J Green, Diane D Allen, Jill A Hollenbach, Jeffrey E Olgin, Gregory M Marcus, Mark J Pletcher, Bruce A C Cree, Jeffrey M Gelfand
Importance: Disability measures in multiple sclerosis (MS) fail to capture potentially important variability in walking behavior. More sensitive and ecologically valid outcome measures are needed to advance MS research. Objectives: To assess continuous step count activity remotely among individuals with MS for 1 year and determine how average daily step count is associated with other measures of MS disability. Design, Setting, and Participants: In a prospective longitudinal observational cohort study, 95 adults with relapsing or progressive MS who were able to walk more than 2 minutes with or without an assistive device were recruited between June 15, 2015, and August 8, 2016, and remotely monitored in their natural environment for 1 year...
March 1, 2019: JAMA Network Open
Martin Diebold, Tobias Derfuss
Background: Multiple sclerosis (MS) is an autoimmune demyelinating disorder of the central nervous system (CNS). Despite improvements of immunomodulatory therapies in relapsing-remitting MS, the pathomechanisms of progressive disease are poorly understood and therapeutically addressed to date. A pathophysiological role for proteins encoded by human endogenous retroviruses (HERVs) has been proposed. GNbAC1 is a monoclonal antibody directed against the envelope protein of a HERV with postulated involvement in MS...
2019: Therapeutic Advances in Neurological Disorders
Tobias D Faizy, Gabriel Broocks, Christian Thaler, Geraldine Rauch, Pimrapat Gebert, Klarissa H Stürner, Fabian Flottmann, Hannes Leischner, Helge C Kniep, Jan-Patrick Stellmann, Christoph Heesen, Jens Fiehler, Susanne Gellißen, Uta Hanning
Background and Objective: In multiple sclerosis (MS) patients, Double Inversion Recovery (DIR) magnetic resonance imaging (MRI) can be used to detect cortical lesions (CL). While the quantity and distribution of CLs seems to be associated with patients' disease course, literature lacks frequent assessments of CL volumes (CL-V) in this context. We investigated the reliability of DIR for the longitudinal assessment of CL-V development with frequent follow-up MRIs and examined the course of CL-V progressions in relation to white-matter lesions (WML), contrast enhancing lesions (CEL) and clinical parameters in patients with Relapsing-Remitting Multiple Sclerosis (RRMS)...
2019: Frontiers in Neurology
N Bergsland, D Ramasamy, E Tavazzi, D Hojnacki, B Weinstock-Guttman, R Zivadinov
BACKGROUND AND PURPOSE: Leptomeningeal inflammation is associated with the development of global cortical gray matter atrophy in multiple sclerosis. However, its association with localized loss of tissue remains unclear. The purpose of this study was to evaluate the relationship between leptomeningeal contrast enhancement, a putative marker of leptomeningeal inflammation, and focal cortical thinning in MS. MATERIALS AND METHODS: Forty-three patients with relapsing-remitting MS and 15 with secondary-progressive MS were imaged on a 3T scanner...
March 14, 2019: AJNR. American Journal of Neuroradiology
Saif Huda, Dan Whittam, Maneesh Bhojak, Jayne Chamberlain, Carmel Noonan, Anu Jacob
Neuromyelitis optica spectrum disorder (NMOSD) is an uncommon antibody-mediated disease of the central nervous system. Long segments of spinal cord inflammation (myelitis), severe optic neuritis, and/or bouts of intractable vomiting and hiccoughs (area postrema syndrome) are classic presentations of the disease and may alert the clinician to the diagnosis. Untreated, approximately 50% of NMOSD patients will be wheelchair users and blind, and a third will have died within 5 years of their first attack. Unlike multiple sclerosis, a progressive clinical course is very unusual and the accrual of disability is related to relapses...
March 2019: Clinical Medicine: Journal of the Royal College of Physicians of London
Stéphanie Hostenbach, Ayla Pauwels, Veronique Michiels, Hubert Raeymaekers, Anne-Marie Van Binst, Annick Van Merhaeghen-Wieleman, Peter Van Schuerbeek, Jacques De Keyser, Miguel D'Haeseleer
BACKGROUND: Axonal degeneration is related to long-term disability in patients with multiple sclerosis (MS). The underlying mechanism remains ill understood but appears to involve axonal energetic dysfunction. A globally impaired cerebral blood flow (CBF) has been observed in the normal-appearing white matter (NAWM) of patients with MS, which is probably related to astrocytic overexpression of endothelin-1 (ET-1). Cerebral hypoperfusion has been associated with reduced mitochondrial activity and disabling symptoms (e...
March 14, 2019: Trials
David Kremer, Peter Göttle, Jose Flores-Rivera, Hans-Peter Hartung, Patrick Küry
PURPOSE OF REVIEW: Medications for relapsing multiple sclerosis (MS) effectively reduce relapse rate, mitigate disability progression and improve MRI measures of inflammation. However, they have virtually no impact on remyelination which is the major mechanism preventing MS-associated neurodegeneration. Stimulating the generation of myelin-(re)producing cells is therefore a central focus of current MS research and a yet unmet clinical need. Here, we present and evaluate key scientific studies from the field of (therapeutic) remyelination research covering the past 1...
March 6, 2019: Current Opinion in Neurology
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"